{"id":2124,"date":"2014-02-06T16:12:06","date_gmt":"2014-02-06T16:12:06","guid":{"rendered":"https:\/\/www.lymphoma.ca\/accord-conclu-entre-pan-canadian-pricing-alliance-et-seattle-genetics-concernant-le-financement-dadcetris\/"},"modified":"2022-01-16T03:06:16","modified_gmt":"2022-01-16T03:06:16","slug":"accord-conclu-entre-pan-canadian-pricing-alliance-et-seattle-genetics-concernant-le-financement-dadcetris","status":"publish","type":"post","link":"https:\/\/www.lymphoma.ca\/fr\/accord-conclu-entre-pan-canadian-pricing-alliance-et-seattle-genetics-concernant-le-financement-dadcetris\/","title":{"rendered":"Accord conclu entre pan-Canadian Pricing Alliance et Seattle Genetics concernant le financement d\u2019ADCETRIS"},"content":{"rendered":"<p>le premier nouveau m\u00e9dicament depuis des d\u00e9cennies \u00e0 \u00eatre particuli\u00e8rement indiqu\u00e9 dans le traitement du lymphome de Hodgkin<br \/>\n<!--more--><\/p>\n<h2>D\u2019excellentes nouvelles pour les patients atteints d\u2019un lymphome!<\/h2>\n<p>ADCETRIS, le premier nouveau m\u00e9dicament depuis des d\u00e9cennies \u00e0 \u00eatre particuli\u00e8rement indiqu\u00e9 dans le traitement du lymphome de Hodgkin et du lymphome anaplasique \u00e0 grandes cellules de type syst\u00e9mique, a \u00e9t\u00e9 approuv\u00e9 pour financement.<\/p>\n<p>Pan-Canadian Pricing Alliance (PCPA) et Seattle Genetics sont parvenus \u00e0 un accord sur le financement du m\u00e9dicament ADCETRIS (brentuximab v\u00e9dotine) pour le traitement des patients atteints du lymphome de Hodgkin et ceux atteints du lymphome anaplasique \u00e0 grandes cellules de type syst\u00e9mique (sALCL), r\u00e9cidivant ou r\u00e9fractaire. Avec prise d\u2019effet le 3 f\u00e9vrier 2014, INESSS a approuv\u00e9 le financement d\u2019ADCETRIS pour le traitement du sALCL, mais son financement dans le cas du lymphome de Hodgkin est officiellement \u00e0 l\u2019\u00e9tude.<\/p>\n<p>Les provinces et territoires participants au PCPA iront de l\u2019avant pour mettre en \u0153uvre le financement individuel en fonction de leurs processus habituels. Pour obtenir plus de renseignements, veuillez communiquer avec votre agence provinciale de financement des m\u00e9dicaments. L\u2019information se rapportant au remboursement des m\u00e9dicaments figure au <a href=\"https:\/\/www.health.gov.on.ca\/en\/pro\/programs\/drugs\/how_drugs_approv\/how_drugs_approv.aspx\">http:\/\/drugcoverage.ca\/en-ca\/<\/a>.<\/p>\n<p>Dans bien des cas, les compagnies d\u2019assurances priv\u00e9es financent le traitement par ADCETRIS, et les patients couverts par une assurance priv\u00e9e sont pri\u00e9s de v\u00e9rifier aupr\u00e8s de leur assureur.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>le premier nouveau m\u00e9dicament depuis des d\u00e9cennies \u00e0 \u00eatre particuli\u00e8rement indiqu\u00e9 dans le traitement du lymphome de Hodgkin<\/p>\n","protected":false},"author":1,"featured_media":1830,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[10],"tags":[],"class_list":{"0":"post-2124","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-nouvelles"},"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v26.7 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Accord conclu entre pan-Canadian Pricing Alliance et Seattle Genetics concernant le financement d\u2019ADCETRIS - Lymphoma Canada<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.lymphoma.ca\/fr\/accord-conclu-entre-pan-canadian-pricing-alliance-et-seattle-genetics-concernant-le-financement-dadcetris\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Accord conclu entre pan-Canadian Pricing Alliance et Seattle Genetics concernant le financement d\u2019ADCETRIS - Lymphoma Canada\" \/>\n<meta property=\"og:description\" content=\"le premier nouveau m\u00e9dicament depuis des d\u00e9cennies \u00e0 \u00eatre particuli\u00e8rement indiqu\u00e9 dans le traitement du lymphome de Hodgkin\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.lymphoma.ca\/fr\/accord-conclu-entre-pan-canadian-pricing-alliance-et-seattle-genetics-concernant-le-financement-dadcetris\/\" \/>\n<meta property=\"og:site_name\" content=\"Lymphoma Canada\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/LymphomaCanada\" \/>\n<meta property=\"article:published_time\" content=\"2014-02-06T16:12:06+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2022-01-16T03:06:16+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.lymphoma.ca\/wp-content\/uploads\/2013\/05\/adcetris_pack.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"700\" \/>\n\t<meta property=\"og:image:height\" content=\"300\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"admin\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@lymphomacanada\" \/>\n<meta name=\"twitter:site\" content=\"@lymphomacanada\" \/>\n<meta name=\"twitter:label1\" content=\"\u00c9crit par\" \/>\n\t<meta name=\"twitter:data1\" content=\"admin\" \/>\n\t<meta name=\"twitter:label2\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/www.lymphoma.ca\/fr\/accord-conclu-entre-pan-canadian-pricing-alliance-et-seattle-genetics-concernant-le-financement-dadcetris\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/www.lymphoma.ca\/fr\/accord-conclu-entre-pan-canadian-pricing-alliance-et-seattle-genetics-concernant-le-financement-dadcetris\/\"},\"author\":{\"name\":\"admin\",\"@id\":\"https:\/\/www.lymphoma.ca\/fr\/#\/schema\/person\/3f654528f96ee33030061e70192633c4\"},\"headline\":\"Accord conclu entre pan-Canadian Pricing Alliance et Seattle Genetics concernant le financement d\u2019ADCETRIS\",\"datePublished\":\"2014-02-06T16:12:06+00:00\",\"dateModified\":\"2022-01-16T03:06:16+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/www.lymphoma.ca\/fr\/accord-conclu-entre-pan-canadian-pricing-alliance-et-seattle-genetics-concernant-le-financement-dadcetris\/\"},\"wordCount\":252,\"publisher\":{\"@id\":\"https:\/\/www.lymphoma.ca\/fr\/#organization\"},\"image\":{\"@id\":\"https:\/\/www.lymphoma.ca\/fr\/accord-conclu-entre-pan-canadian-pricing-alliance-et-seattle-genetics-concernant-le-financement-dadcetris\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.lymphoma.ca\/wp-content\/uploads\/2013\/05\/adcetris_pack.jpg\",\"articleSection\":[\"Nouvelles\"],\"inLanguage\":\"fr-FR\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.lymphoma.ca\/fr\/accord-conclu-entre-pan-canadian-pricing-alliance-et-seattle-genetics-concernant-le-financement-dadcetris\/\",\"url\":\"https:\/\/www.lymphoma.ca\/fr\/accord-conclu-entre-pan-canadian-pricing-alliance-et-seattle-genetics-concernant-le-financement-dadcetris\/\",\"name\":\"Accord conclu entre pan-Canadian Pricing Alliance et Seattle Genetics concernant le financement d\u2019ADCETRIS - Lymphoma Canada\",\"isPartOf\":{\"@id\":\"https:\/\/www.lymphoma.ca\/fr\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/www.lymphoma.ca\/fr\/accord-conclu-entre-pan-canadian-pricing-alliance-et-seattle-genetics-concernant-le-financement-dadcetris\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/www.lymphoma.ca\/fr\/accord-conclu-entre-pan-canadian-pricing-alliance-et-seattle-genetics-concernant-le-financement-dadcetris\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.lymphoma.ca\/wp-content\/uploads\/2013\/05\/adcetris_pack.jpg\",\"datePublished\":\"2014-02-06T16:12:06+00:00\",\"dateModified\":\"2022-01-16T03:06:16+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/www.lymphoma.ca\/fr\/accord-conclu-entre-pan-canadian-pricing-alliance-et-seattle-genetics-concernant-le-financement-dadcetris\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.lymphoma.ca\/fr\/accord-conclu-entre-pan-canadian-pricing-alliance-et-seattle-genetics-concernant-le-financement-dadcetris\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/www.lymphoma.ca\/fr\/accord-conclu-entre-pan-canadian-pricing-alliance-et-seattle-genetics-concernant-le-financement-dadcetris\/#primaryimage\",\"url\":\"https:\/\/www.lymphoma.ca\/wp-content\/uploads\/2013\/05\/adcetris_pack.jpg\",\"contentUrl\":\"https:\/\/www.lymphoma.ca\/wp-content\/uploads\/2013\/05\/adcetris_pack.jpg\",\"width\":700,\"height\":300},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.lymphoma.ca\/fr\/accord-conclu-entre-pan-canadian-pricing-alliance-et-seattle-genetics-concernant-le-financement-dadcetris\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.lymphoma.ca\/fr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Accord conclu entre pan-Canadian Pricing Alliance et Seattle Genetics concernant le financement d\u2019ADCETRIS\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.lymphoma.ca\/fr\/#website\",\"url\":\"https:\/\/www.lymphoma.ca\/fr\/\",\"name\":\"Lymphoma Canada\",\"description\":\"Information. Help. Hope.\",\"publisher\":{\"@id\":\"https:\/\/www.lymphoma.ca\/fr\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.lymphoma.ca\/fr\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.lymphoma.ca\/fr\/#organization\",\"name\":\"Lymphoma Canada\",\"url\":\"https:\/\/www.lymphoma.ca\/fr\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/www.lymphoma.ca\/fr\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.lymphoma.ca\/wp-content\/uploads\/2023\/05\/logo-lymphoma.jpg\",\"contentUrl\":\"https:\/\/www.lymphoma.ca\/wp-content\/uploads\/2023\/05\/logo-lymphoma.jpg\",\"width\":343,\"height\":343,\"caption\":\"Lymphoma Canada\"},\"image\":{\"@id\":\"https:\/\/www.lymphoma.ca\/fr\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/LymphomaCanada\",\"https:\/\/x.com\/lymphomacanada\",\"https:\/\/www.linkedin.com\/company\/lymphoma-canada\/\",\"http:\/\/instagram.com\/lymphomacanada\",\"http:\/\/www.youtube.com\/user\/LymphomaTV\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.lymphoma.ca\/fr\/#\/schema\/person\/3f654528f96ee33030061e70192633c4\",\"name\":\"admin\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/www.lymphoma.ca\/fr\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/f8f0e240f88d3162ad64d22cede41425?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/f8f0e240f88d3162ad64d22cede41425?s=96&d=mm&r=g\",\"caption\":\"admin\"},\"url\":\"https:\/\/www.lymphoma.ca\/fr\/author\/erezz_oxmaxp0p\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Accord conclu entre pan-Canadian Pricing Alliance et Seattle Genetics concernant le financement d\u2019ADCETRIS - Lymphoma Canada","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.lymphoma.ca\/fr\/accord-conclu-entre-pan-canadian-pricing-alliance-et-seattle-genetics-concernant-le-financement-dadcetris\/","og_locale":"fr_FR","og_type":"article","og_title":"Accord conclu entre pan-Canadian Pricing Alliance et Seattle Genetics concernant le financement d\u2019ADCETRIS - Lymphoma Canada","og_description":"le premier nouveau m\u00e9dicament depuis des d\u00e9cennies \u00e0 \u00eatre particuli\u00e8rement indiqu\u00e9 dans le traitement du lymphome de Hodgkin","og_url":"https:\/\/www.lymphoma.ca\/fr\/accord-conclu-entre-pan-canadian-pricing-alliance-et-seattle-genetics-concernant-le-financement-dadcetris\/","og_site_name":"Lymphoma Canada","article_publisher":"https:\/\/www.facebook.com\/LymphomaCanada","article_published_time":"2014-02-06T16:12:06+00:00","article_modified_time":"2022-01-16T03:06:16+00:00","og_image":[{"width":700,"height":300,"url":"https:\/\/www.lymphoma.ca\/wp-content\/uploads\/2013\/05\/adcetris_pack.jpg","type":"image\/jpeg"}],"author":"admin","twitter_card":"summary_large_image","twitter_creator":"@lymphomacanada","twitter_site":"@lymphomacanada","twitter_misc":{"\u00c9crit par":"admin","Dur\u00e9e de lecture estim\u00e9e":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.lymphoma.ca\/fr\/accord-conclu-entre-pan-canadian-pricing-alliance-et-seattle-genetics-concernant-le-financement-dadcetris\/#article","isPartOf":{"@id":"https:\/\/www.lymphoma.ca\/fr\/accord-conclu-entre-pan-canadian-pricing-alliance-et-seattle-genetics-concernant-le-financement-dadcetris\/"},"author":{"name":"admin","@id":"https:\/\/www.lymphoma.ca\/fr\/#\/schema\/person\/3f654528f96ee33030061e70192633c4"},"headline":"Accord conclu entre pan-Canadian Pricing Alliance et Seattle Genetics concernant le financement d\u2019ADCETRIS","datePublished":"2014-02-06T16:12:06+00:00","dateModified":"2022-01-16T03:06:16+00:00","mainEntityOfPage":{"@id":"https:\/\/www.lymphoma.ca\/fr\/accord-conclu-entre-pan-canadian-pricing-alliance-et-seattle-genetics-concernant-le-financement-dadcetris\/"},"wordCount":252,"publisher":{"@id":"https:\/\/www.lymphoma.ca\/fr\/#organization"},"image":{"@id":"https:\/\/www.lymphoma.ca\/fr\/accord-conclu-entre-pan-canadian-pricing-alliance-et-seattle-genetics-concernant-le-financement-dadcetris\/#primaryimage"},"thumbnailUrl":"https:\/\/www.lymphoma.ca\/wp-content\/uploads\/2013\/05\/adcetris_pack.jpg","articleSection":["Nouvelles"],"inLanguage":"fr-FR"},{"@type":"WebPage","@id":"https:\/\/www.lymphoma.ca\/fr\/accord-conclu-entre-pan-canadian-pricing-alliance-et-seattle-genetics-concernant-le-financement-dadcetris\/","url":"https:\/\/www.lymphoma.ca\/fr\/accord-conclu-entre-pan-canadian-pricing-alliance-et-seattle-genetics-concernant-le-financement-dadcetris\/","name":"Accord conclu entre pan-Canadian Pricing Alliance et Seattle Genetics concernant le financement d\u2019ADCETRIS - Lymphoma Canada","isPartOf":{"@id":"https:\/\/www.lymphoma.ca\/fr\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.lymphoma.ca\/fr\/accord-conclu-entre-pan-canadian-pricing-alliance-et-seattle-genetics-concernant-le-financement-dadcetris\/#primaryimage"},"image":{"@id":"https:\/\/www.lymphoma.ca\/fr\/accord-conclu-entre-pan-canadian-pricing-alliance-et-seattle-genetics-concernant-le-financement-dadcetris\/#primaryimage"},"thumbnailUrl":"https:\/\/www.lymphoma.ca\/wp-content\/uploads\/2013\/05\/adcetris_pack.jpg","datePublished":"2014-02-06T16:12:06+00:00","dateModified":"2022-01-16T03:06:16+00:00","breadcrumb":{"@id":"https:\/\/www.lymphoma.ca\/fr\/accord-conclu-entre-pan-canadian-pricing-alliance-et-seattle-genetics-concernant-le-financement-dadcetris\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.lymphoma.ca\/fr\/accord-conclu-entre-pan-canadian-pricing-alliance-et-seattle-genetics-concernant-le-financement-dadcetris\/"]}]},{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/www.lymphoma.ca\/fr\/accord-conclu-entre-pan-canadian-pricing-alliance-et-seattle-genetics-concernant-le-financement-dadcetris\/#primaryimage","url":"https:\/\/www.lymphoma.ca\/wp-content\/uploads\/2013\/05\/adcetris_pack.jpg","contentUrl":"https:\/\/www.lymphoma.ca\/wp-content\/uploads\/2013\/05\/adcetris_pack.jpg","width":700,"height":300},{"@type":"BreadcrumbList","@id":"https:\/\/www.lymphoma.ca\/fr\/accord-conclu-entre-pan-canadian-pricing-alliance-et-seattle-genetics-concernant-le-financement-dadcetris\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.lymphoma.ca\/fr\/"},{"@type":"ListItem","position":2,"name":"Accord conclu entre pan-Canadian Pricing Alliance et Seattle Genetics concernant le financement d\u2019ADCETRIS"}]},{"@type":"WebSite","@id":"https:\/\/www.lymphoma.ca\/fr\/#website","url":"https:\/\/www.lymphoma.ca\/fr\/","name":"Lymphoma Canada","description":"Information. Help. Hope.","publisher":{"@id":"https:\/\/www.lymphoma.ca\/fr\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.lymphoma.ca\/fr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Organization","@id":"https:\/\/www.lymphoma.ca\/fr\/#organization","name":"Lymphoma Canada","url":"https:\/\/www.lymphoma.ca\/fr\/","logo":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/www.lymphoma.ca\/fr\/#\/schema\/logo\/image\/","url":"https:\/\/www.lymphoma.ca\/wp-content\/uploads\/2023\/05\/logo-lymphoma.jpg","contentUrl":"https:\/\/www.lymphoma.ca\/wp-content\/uploads\/2023\/05\/logo-lymphoma.jpg","width":343,"height":343,"caption":"Lymphoma Canada"},"image":{"@id":"https:\/\/www.lymphoma.ca\/fr\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/LymphomaCanada","https:\/\/x.com\/lymphomacanada","https:\/\/www.linkedin.com\/company\/lymphoma-canada\/","http:\/\/instagram.com\/lymphomacanada","http:\/\/www.youtube.com\/user\/LymphomaTV"]},{"@type":"Person","@id":"https:\/\/www.lymphoma.ca\/fr\/#\/schema\/person\/3f654528f96ee33030061e70192633c4","name":"admin","image":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/www.lymphoma.ca\/fr\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/f8f0e240f88d3162ad64d22cede41425?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/f8f0e240f88d3162ad64d22cede41425?s=96&d=mm&r=g","caption":"admin"},"url":"https:\/\/www.lymphoma.ca\/fr\/author\/erezz_oxmaxp0p\/"}]}},"_links":{"self":[{"href":"https:\/\/www.lymphoma.ca\/fr\/wp-json\/wp\/v2\/posts\/2124","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.lymphoma.ca\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.lymphoma.ca\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.lymphoma.ca\/fr\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.lymphoma.ca\/fr\/wp-json\/wp\/v2\/comments?post=2124"}],"version-history":[{"count":1,"href":"https:\/\/www.lymphoma.ca\/fr\/wp-json\/wp\/v2\/posts\/2124\/revisions"}],"predecessor-version":[{"id":11388,"href":"https:\/\/www.lymphoma.ca\/fr\/wp-json\/wp\/v2\/posts\/2124\/revisions\/11388"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.lymphoma.ca\/fr\/wp-json\/wp\/v2\/media\/1830"}],"wp:attachment":[{"href":"https:\/\/www.lymphoma.ca\/fr\/wp-json\/wp\/v2\/media?parent=2124"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.lymphoma.ca\/fr\/wp-json\/wp\/v2\/categories?post=2124"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.lymphoma.ca\/fr\/wp-json\/wp\/v2\/tags?post=2124"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}